ABSTRACT
Background: The clinical characteristics of patients who had lymph node-negative early breast cancer were assessed.
Methods: We assessed a total of 579 patients in the study, including 74 patients (12.8%) with T1a, 119 patients (20.7%) and 367 patients (63.7%) with T1c. Patients with T1 tumors were further classified into 3 groups according to hormone receptor (HR) and HER-2 status.
Results: In patients with T1a, the disease-free survival (DFS) rate was 98.4% at 2 years (p=0.000). In subgroup analysis of early breast cancers, 10-year-DFS rates of the patients in HR (+)/HER2 (-), HR (-) /HER2 (+) and HR (-)/HER2 (-) subgroups were no significant difference (p = 0.917).
Conclusion: The T1a group had a worse prognosis than T1b and T1c groups in second years (p=0.000), but there was no statistically important difference between subgroups (p=0.917). Although there are differences in patients and tumor features, the prognosis of patients with T1a, b, cN0M0 breast cancer is excellent.
Manuscripts that are “Published at Acceptance” have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear prior to being copy edited or formatted in the style guide of this Journal. The contents of the manuscript may change before it is published in its final form. While accepted manuscripts are not yet assigned a volume, issue, or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. Manuscripts in this section will be removed once they have been assigned to a volume and issue, but will still retain the DOI and date of e-publication.
Our 7 faculties and 12 professional schools offer more than 200 programmes to some 18,000 graduate, undergraduate and continuing studies students.
The UWI, Mona ranks first in Jamaica among accredited tertiary-level programmes. In 2012, the University was again one of Jamaica’s Top 100 Employers.
© Copyright 2014-2026 | Disclaimer | Privacy Statement
